Gantenerumab for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 6 Mar 2020: Trial completed, NCT04623242
  2. 10 Nov 2020: Trial registered, NCT04623242

The trials

NCT04623242: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

State
Completed
Phase
Phase 2 and Phase 3
People
194 taking part
Started
Dec 2012
Primary completion
22 Nov 2019
Arms
Gantenerumab
Results
Posted on the registry
Papers
doi:10.1001/jamaneurol.2024.0991, doi:10.1136/bmjno-2022-000335
  1. 6 Mar 2020: Trial completed
  2. 10 Nov 2020: Trial registered
  3. 22 Sep 2022: Trial results posted

NCT05256134: A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)

State
Stopped early
Phase
Phase 3
People
25 taking part
Started
19 Apr 2022
Primary completion
13 Mar 2023
Arms
Gantenerumab
Results
Posted on the registry
Papers
doi:10.1002/alz.70676, doi:10.1002/alz.71009
  1. 25 Feb 2022: Trial registered
  2. 19 Apr 2022: Trial started
  3. 13 Mar 2023: Trial terminated
  4. 9 Jul 2024: Trial results posted

NCT06424236: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

State
Stopped early
Phase
Phase 2 and Phase 3
People
73 taking part
Started
3 Jun 2020
Primary completion
6 Oct 2023
Arms
Gantenerumab Open Label Extension
Results
Posted on the registry
Papers
doi:10.1016/s1474-4422(25)00024-9, doi:10.1101/2024.10.29.24316289
  1. 3 Jun 2020: Trial started
  2. 13 Nov 2023: Trial terminated
  3. 22 May 2024: Trial registered
  4. 4 Feb 2025: Trial results posted

How the status changed

  1. 16 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.